By using our website, you agree to the use of cookies as described in our Cookie Policy.

Close
Consilium-white-out.png Consilium Final logo.png Menu
Close
Twitter
  • About Us
    • Healthcare
    • Our values
  • Our expertise
    • Overview
      • Overview
    • Our experience
    • Case studies
      • Alliance for Regenerative Medicine
      • Sensyne Health
      • Cancer Research UK
      • Cambridge Innovation Capital
      • Vectura
      • CMR Surgical
      • Horizon Discovery
      • Immunocore
      • Quanta
  • Our team
  • News & insights
    • Consilium news
    • Consilium Conscience
    • Monthly intel
    • Events calendar
    • Email Alerts
  • Careers
  • Contact us

Consilium news

  • Home/
  • News & insights/
  • Consilium news/
  • Consilium Strategic Communications Advises Arvelle Therapeutics From...

News & insights

  • Consilium news
  • Consilium Conscience
  • Monthly intel
  • Events calendar
  • Email Alerts
Tweets by ConsiliumHC

06th January 2021

 

Consilium Strategic Communications Advises Arvelle Therapeutics From Inception Through Its Successful Acquisition by Angelini Pharma

 

London, 6 January 2021, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have advised Arvelle Therapeutics on its strategic communications since its inception and culminating in its acquisition by Angelini Pharma for a total aggregate valuation of up to $960 million.

Arvelle Therapeutics is an emerging biopharmaceutical company focused on bringing innovative solutions to patients suffering from CNS disorders.  Since its founding in 2019, Arvelle’s management team has focused on bringing cenobamate to people with epilepsy in Europe. Following Angelini Pharma’s acquisition of Arvelle Therapeutics, Angelini Pharma will have the exclusive license to commercialize cenobamate in the European Union and other countries in the European Economic Area (Switzerland and the United Kingdom).

 The team advising Arvelle Therapeutics at Consilium was Mary-Jane Elliott, Susan Stuart, Alex Harrison, Lindsey Neville, Carina Jurs and Kris Lam. Centerview Partners UK LLP acted as sole financial advisor and Sidley Austin LLP and NautaDutilh N.V. provided legal counsel to Arvelle Therapeutics during the acquisition.

 

“It has been a pleasure to work with the team at Arvelle. Since its launch in 2019, Arvelle has made significant progress towards launching cenobamate in Europe and we are delighted for the management team and company on securing this deal which has also created significant value for shareholders.”

Mary-Jane Elliott

Managing Partner of Consilium Strategic Communications

“We are grateful to the team at Consilium for their strategic advice and guidance since we started working with them in 2019 and through this acquisition. They have been a close advisor to the senior management team and I have been impressed by the team’s sector knowledge and professionalism.”

Mark Altmeyer

President & CEO of Arvelle Therapeutics

-ENDS-

 

For more information, please contact:

 

Consilium Strategic Communications

Mary-Jane Elliott / Amber Fennell

Tel: +44(0)20 3709 5700

info@consilium-comms.com

www.consilium-comms.com

Follow us: @consiliumhc

                                                                               

About Consilium Strategic Communications

 

Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory with offices in Europe and across the US. Consilium's highly skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications and IR programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE100, FTSEurofirst 300 and FTSE250, through to discrete specialist reputation management projects.

 

 


Back to previous page
Twitter

Consilium Healthcare - RT @Gait_Q: We are delighted to announce that #gaitQ has been awarded a £135,000 grant by the UK’s @NIHRresearch for the continued developm…

  • 337h
Register for news and updates Line
  • Twitter
  • LinkedIn
  • Email

©2021 Consilium Strategic Communications

  • Accessibility
  • Privacy and cookie policy
  • Sitemap

emperor.works